Non-natural ribonuclease conjugates as cytotoxic agents
AssigneeQuintessence Biosciences, Inc.
InventorsLaura E. Strong, Peter A. Leland, Thomas Burke
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.
Claims18
-20. (canceled)
A composition comprising tumor-cell specific monoclonal immunoglobulin or fragment thereof conjugated to a variant of ribonuclease one (human RNase I) of SEQ ID NO:2, wherein said variant ribonuclease comprises an arginine as position 38, as well as:
- a) two or more changes in region 86-91;
- b) a change at position 39;
- c) a change to a cysteine at a position 1-6;
- and
- d) a change to a cysteine at a position 116-121.
Dependencies are inferred from the claim text.